HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Avon Q1

This article was originally published in The Rose Sheet

Executive Summary

Promotions of value-driven products, defined as offering great quality for affordable prices, drove beauty unit growth of 2% in the first quarter, Avon Chairman and CEO Andrea Jung said in a May 5 earnings release. Advertising spend of $78 mil. in the quarter helped support "smart value" products, such as Christian La Croix fragrance Absynthe and Derma-Full skin care, firm notes. Net beauty sales fell 12% (representing growth of 5% on a local-currency basis) to $1.56 billion, with color cosmetics leading the categories with 10% growth. Skin care sales were down 4%. Overall revenue was $2.2 bil., representing a decline of 13% on a year-over-year basis (up 3% on a local currency basis). Sluggish sales drove net income down 37% to $117.5 mil

You may also be interested in...



DevaCurl Faces Multiple Class Actions As Latest Brand Linked To Hair Loss

The company maintains that its products are safe, but plaintiffs in proposed class actions allege it has knowingly put consumers at risk of hair loss and other injuries. DevaCurl’s troubles escalated quickly after a former brand ambassador went viral with a 31 January video urging consumers to stop using DevaCurl products and adopt safer alternatives.

Could ICER Outreach To US FDA Lead To Better Cost Effectiveness Analyses?

To aid its value assessments, ICER is interested in helping FDA understand the importance of patient-relevant outcomes and consistent endpoints across trials of drugs for the same disease.

Seretide Settlement To Lift Glenmark’s Europe Business

Glenmark can sell its partnered generic rival to GSK’s Seretide Accuhaler dry powder inhaler in certain European markets following a settlement with the UK company. The Indian firm has also shelved divestment plans for its API business, at least for now.

UsernamePublicRestriction

Register

RS016138

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel